Protagonist Therapeutics
PTGX
317 hedge funds and large institutions have $8.3B invested in Protagonist Therapeutics in 2026 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 110 increasing their positions, 102 reducing their positions, and 47 closing their positions.
225% more call options, than puts
Call options by funds: $36.2M | Put options by funds: $11.1M
34% more capital invested
Capital invested by funds: $6.18B → $8.3B (+$2.12B)
26% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 47
10.28% more ownership
Funds ownership: 113.13% → 123.41% (+10%)
1% more funds holding
Funds holding: 313 → 317 (+4)
8% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 102
23% less funds holding in top 10
Funds holding in top 10: 13 → 10 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$213M |
| 2 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$73.4M |
| 3 |
Jennison Associates
New York
|
+$65.6M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$52.8M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$37.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$39.3M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$35.1M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$33.5M |
| 4 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$18M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$17.4M |
PTGX Hedge Fund Activity: Q1 2026 in Review
317 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q1 2026, worth a combined $8.3B — up 34% from $6.18B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new PTGX positions and 47 closed out — a net gain of 12 holders — while 110 added to existing stakes and 102 trimmed.
The largest buyer was UBS Group, adding an estimated $213M. The largest seller was Commodore Capital, exiting entirely with an estimated $39.3M sold.
- 317 institutional investors held Protagonist Therapeutics (PTGX) as of Q1 2026, up from 313 in Q4 2025.
- Funds reported $8.3B of Protagonist Therapeutics stock for Q1 2026, up 34% quarter-over-quarter.
- 59 funds opened new Protagonist Therapeutics positions in Q1 2026 and 47 closed out, a net change of +12 holders.
- The largest Protagonist Therapeutics buyer in Q1 2026 was UBS Group, an estimated $213M added.
- The largest Protagonist Therapeutics seller in Q1 2026 was Commodore Capital, an estimated $39.3M sold.
Based on aggregated 13F filings for Q1 2026.